{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-008525","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2022-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.423514+00:00","generated_at":"2026-06-25T22:18:29.219740+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sutro Biopharma Q1 2022 revenue $5.9M; cash $192.1M; STRO-002 data expected H2 2022","bullets":["Revenue $5.9M vs $14.7M YoY; operating expenses $45.0M vs $33.7M; net loss not stated directly.","Cash, cash equivalents and marketable securities $192.1M as of Mar 31, 2022; runway into H2 2023.","Phase 1 dose-expansion data for STRO-002 (ovarian cancer) expected H2 2022; regulatory meetings planned mid-2022.","First patient dosed in STRO-002 + bevacizumab combo trial; endometrial cohort enrolling.","Tasly amended STRO-002 license: $25M upfront, up to $350M in milestones; Tasly to fund Greater China development."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-008525","json":"https://secwatch.observer/filing/0000950170-22-008525.json","markdown":"https://secwatch.observer/filing/0000950170-22-008525.md","text":"https://secwatch.observer/filing/0000950170-22-008525.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017022008525/0000950170-22-008525-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017022008525/stro-20220509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:18:29.219740+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}